RenovoCyte enters strategic partnership with VetCell to use stem cell therapy and Wellness Banking
RenovoCyte, LLC announced a strategic partnership with Equine Partners of America (EPA) doing business as VetCell Americas. VetCell enjoys a well-established equine stem cell business in the United Kingdom and is now moving into the United States with the help of EPA in Atlanta, GA. RenovoCyte, LLC will be responsible for the processing of VetCell's mesenchymal stem cells from equine bone marrow and in-house veterinary support for VetCell's equine treatments in the USA.
VetCell Americas also acquired an agreement from RenovoCyte, LLC to carry RenovoCyte's equine intravenous stem cell product, Autocell-EQ. RenovoCyte's innovative stem cell technology allows intravenous treatments of exercise induced pulmonary hemorrhage (bleeders), rhabdomyolysis (tying up) and osteoarthritis in the horse. RenovoCyte Cellular Medicine Laboratories in the U.S. isolates multipotent stem cells from innovative sources such as the wolf teeth, skin biopsies, placenta and testes then cryopreserves the sample using their Wellness BankingTM protocol or cultures the cells to a known dose for autologous intravenous therapy.
"We are excited to partner with VetCell in order to help apply their equine products to U.S. customers. VetCell's experience, reputation, and success in the European market allow us to start with a very stable technology platform." said Dr. Shelly Zacharias, DVM, Director of Veterinary Operations for RenovoCyte, LLC.
Other news from the department business & finance
